T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion

BACKGROUND: T cell receptor (TCR)-engineered cells can be powerful tools in the treatment of malignancies. However, tumor resistance by Human Leukocyte antigen (HLA) class I downregulation can negatively impact the success of any TCR-mediated cell therapy. Allogeneic natural killer (NK) cells have d...

Descripción completa

Detalles Bibliográficos
Autores principales: Morton, Laura T, Wachsmann, Tassilo L A, Meeuwsen, Miranda H, Wouters, Anne K, Remst, Dennis F G, van Loenen, Marleen M, Falkenburg, J H Frederik, Heemskerk, Mirjam H M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921915/
https://www.ncbi.nlm.nih.gov/pubmed/35288464
http://dx.doi.org/10.1136/jitc-2021-003715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921915/
https://www.ncbi.nlm.nih.gov/pubmed/35288464
http://dx.doi.org/10.1136/jitc-2021-003715

Ejemplares similares